PDE4

PDE4 (phosphodiesterase 4) is a cAMP-specific phosphodiesterase family that terminates intracellular cAMP signaling through hydrolysis of cyclic adenosine monophosphate, thereby regulating multiple inflammatory and immune responses^[1][2]. PDE4-mediated control of cAMP signaling influences the activity of immune and resident tissue cells, including T lymphocytes, macrophages, monocytes, neutrophils, and epithelial cells, placing this enzyme family at the center of inflammatory signaling networks^[1][3]. Mechanistically, inhibition of PDE4 elevates intracellular cAMP levels and suppresses the production and release of pro-inflammatory mediators, which has established PDE4 as a therapeutic target in chronic inflammatory diseases and experimental models of airway and immune dysfunction^[1][3][4]. Disease relevance is supported by the clinical development and approval of PDE4 inhibitors for conditions such as chronic obstructive pulmonary disease, psoriatic arthritis, and atopic dermatitis, where modulation of inflammatory pathways contributes to therapeutic benefit^[3][4]. Compared with related isoforms, the PDE4 family comprises four gene subfamilies, PDE4A, PDE4B, PDE4C, and PDE4D, with PDE4A, PDE4B, and PDE4D highly represented in immune cells, whereas PDE4C expression is generally limited in these cellular contexts^[1]. Importantly, PDE4B has been associated with anti-inflammatory pharmacology, whereas PDE4D has been linked to nausea and emesis observed with nonselective PDE4 inhibition, motivating the development of subtype-selective inhibitors^[3][5]. For experimental applications, inhibitors such as roflumilast, apremilast, and crisaborole are widely used to investigate cAMP-dependent regulation of inflammation and to evaluate isoform-selective pharmacological strategies^[3][4].